Amazon Disrupts Obesity Drug Market with Integrated GLP-1 Care Program

Amazon has officially entered the high-growth obesity medication market, launching a comprehensive GLP-1 management program designed to integrate weight loss treatment into primary care. By utilizing Amazon One Medical for clinical oversight and Amazon Pharmacy for fulfillment, the company aims to treat obesity as a chronic condition rather than a series of isolated prescriptions. This vertical integration allows Amazon to offer a seamless pipeline from virtual consultation to doorstep delivery. The program provides access to leading treatments, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, as well as newer oral GLP-1 options. Pricing for insured patients starts as low as $25 per month, while cash-paying customers can access oral medications starting at $149 and injectables starting at $299 per month. A key competitive advantage is Amazon's logistics network. The company plans to expand same-day drug delivery to 4,500 cities by the end of 2026. Additionally, the company is introducing on-demand prescription renewals, with message consultations starting at $29 and video care at $49. The announcement triggered immediate volatility for competitors in the weight-loss and telehealth space. Shares of Hims & Hers Health, Viking Therapeutics, Amgen, and Septerna all declined following the news, reflecting investor concerns over Amazon's ability to capture market share through superior convenience and pricing transparency.